These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25003557)

  • 21. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data.
    Mudde SE; Ayoun Alsoud R; van der Meijden A; Upton AM; Lotlikar MU; Simonsson USH; Bax HI; de Steenwinkel JEM
    J Infect Dis; 2022 Jun; 225(11):1876-1885. PubMed ID: 33606880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.
    Santos NCS; Scodro RBL; de Almeida AL; Baldin VP; Nakamura de Vasconcelos SS; Siqueira VLD; Caleffi-Ferracioli KR; Campanerut-Sá PAZ; Cardoso RF
    Tuberculosis (Edinb); 2018 Jul; 111():41-44. PubMed ID: 30029913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.
    Srivastava S; Sherman C; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5085-9. PubMed ID: 21896907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of minimum bactericidal concentration, in single or combination drugs, against
    Santos NCS; Scodro RBL; Leal DC; do Prado SM; Micheletti DF; Sampiron EG; Costacurta GF; de Almeida AL; da Silva LA; Ieque AL; Ghiraldi Lopes LD; de Pádua RA; Siqueira VL; Caleffi-Ferracioli KR; Cardoso RF
    Future Microbiol; 2020 Jan; 15():107-114. PubMed ID: 32064924
    [No Abstract]   [Full Text] [Related]  

  • 27. Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.
    van Rijn SP; Srivastava S; Wessels MA; van Soolingen D; Alffenaar JC; Gumbo T
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
    Drusano GL; Kim S; Almoslem M; Schmidt S; D'Argenio DZ; Myrick J; Duncanson B; Nole J; Brown D; Peloquin CA; Neely M; Yamada W; Louie A
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying Regimens Containing TBI-166, a New Drug Candidate against
    Zhang Y; Zhu H; Fu L; Wang B; Guo S; Chen X; Liu Z; Huang H; Yang T; Lu Y
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of Moxifloxacin against
    Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Trends in tuberculosis treatment duration].
    Veziris N; Aubry A; Truffot-Pernot C
    Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using
    Genestet C; Ader F; Pichat C; Lina G; Dumitrescu O; Goutelle S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.
    Srivastava S; Magombedze G; Koeuth T; Sherman C; Pasipanodya JG; Raj P; Wakeland E; Deshpande D; Gumbo T
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
    Park SW; Tasneen R; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin.
    Khara JS; Wang Y; Ke XY; Liu S; Newton SM; Langford PR; Yang YY; Ee PL
    Biomaterials; 2014 Feb; 35(6):2032-8. PubMed ID: 24314557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109.
    de Knegt GJ; van der Meijden A; de Vogel CP; Aarnoutse RE; de Steenwinkel JE
    Int J Antimicrob Agents; 2017 Mar; 49(3):302-307. PubMed ID: 28162983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.